After being stuck in the mud for 3 years, are CSL shares a buy today?

Is it buy or sell for CSL today?

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares used to be a rather bulletproof investment, or so it seemed 
  • For almost a decade, the CSL share price mostly went up 
  • But CSL has been stuck in neutral for a while now. So could it be a buy today? 

The CSL Limited (ASX: CSL) share price used to be one of the most seemingly bulletproof investments on the ASX. For years and years, it seemed CSL shares could only go up. And this was true for a time. CSL spent eight years from 2012 to 2020 rising from around $30 to over $300, finally topping out at roughly $336 a share in February 2020.

But the past three years have been a very different story for CSL shares. Since reaching the all-time high of $336 a share in February 2020, CSL has yet to reclaim that high. In fact, the company is today sitting at just over $273 a share at the time of writing. That's a good 19% or so away from CSL's high watermark. The first time CSL hit $270 a share, it was back in late 2019. That means that for almost three years, CSL shares have been stuck in the mud. On today's pricing, the company remains down by 6.5% over the past 12 months, and down close to 8% in 2022 so far.

So is it winner to loser for CSL? Or does this meandering share price performance give investors a compelling buy case for CSL today?

Are CSL shares a buy today?

Well, ASX broker Citi reckons it's the latter. As my Fool colleague James covered last week, Citi is currently a fan of CSL shares. It has given the ASX 200 healthcare giant a buy rating and a 12-month share price target of $335 – back to its old all-time high. The broker reckons that CSL will continue to benefit from improved plasma collections and "strong underlying demand" for its products.

But Citi isn't the only fan of CSL shares right now. My Fool colleague Tony covered an ASX fund manager's opinion on CSL this morning, and it was also a bullish one. Catapult Wealth portfolio manager Tim Haselum named CSL as one of the two ASX shares he reckons is a best buy now. Haselum pointed to CSL's "lifesaving and non-discretionary nature", as well as its track record in making lucrative acquisitions, for this optimism.

So that's how two ASX expert investors are viewing CSL shares right now. The CSL share price has been stuck in the mud for a few years. But if these two investors are to be believed, it might just hit the road again soon.

At the current CSL share price, this ASX 200 healthcare share has a market capitalisation of $131.56 billion, with a dividend yield of 0.95%.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »